One common genetic hallmark of diffuse astrocytomas and oligodendrogliomas is the IDH-mutation, which is presented on the major histocompatibility complex (MHC) class II [36], making mutant IDH a potential target for immunotherapy and suitable for vaccination approaches. This evidence concerns the gene IDH1 and oligodendroglioma.